Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study Meeting Abstract

  

Authors:	Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; Costello, R.; Zhang, Y.; Mulquin, M.; Lamping, L.; Carpenter, A.; Roberson, B.; Maric, I.; Calvo, K. R.; Braylan, R. C.; Yuan, C. M.; Stetler-Stevenson, M.; Arthur, D. C.; Lindenberg, L.; Kurdziel, K. A.; Choyke, P.; Steinberg, S. M.; Figg, W.; Wilson, W. H.; Landgren, O.
Abstract Title:	Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study
Meeting Title:	58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	128
Issue:	22
Meeting Dates:	2016 Dec 3-6
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2016-12-02
Language:	English
ACCESSION:	WOS:000394452505030
PROVIDER:	wos
DOI:	10.1182/blood.V128.22.3339.3339
Notes:	Meeting Abstract: 3339 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/127249